Pediatric Interstitial Lung Disease Tied to Novel Disorder with Genetic Causes
Researchers linked loss-of-function variants in the TMEM63B gene to a novel disorder causing interstitial lung disease in some pediatric patients.
Tag: interstitial lung disease
All
Latest
Pediatric Interstitial Lung Disease Tied to Novel Disorder with Genetic Causes
Researchers linked loss-of-function variants in the TMEM63B gene to a novel disorder causing interstitial lung disease in some pediatric patients.
Read More
New Data on Inhaled Treprostinil for IPF
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More
Lung Comorbidities Influence ILD Risk in Rheumatoid Arthritis
When comorbidity burden was assessed using the Rheumatic Disease Comorbidity Index (RDCI), higher scores were significantly associated with ILD development.
Read More
Insmed Presents Data on TPIP Inhalation Drug for PAH
Insmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP), being evaluated as a once-daily therapy for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders.
Read More
Case Report: Novel Treatment for Fibrosing Mediastinitis
A new case report describes a novel approach for treating fibrosing mediastinitis using rituximab injections directly into mediastinal lymph nodes combined with pulmonary artery angioplasty.
Read More
Inhaled Treprostinil Improves Cardiac Effort in PH-ILD Patients
Treatment with an inhaled dry powder formulation of treprostinil was associated with improvements in cardiac effort for patients with pulmonary hypertension–interstitial lung disease (PH-ILD).
Read More
Group Singing Program Improved Lung Disease Symptoms
A weekly 90-minute online group singing session delivered for 12 weeks over Zoom was associated with improved quality of life in patients with COPD or interstitial lung disease.
Read More
FDA Clears Screening Algorithm to Assess for Interstitial Lung Disease
The AI-powered tool automatically assesses medical data for interstitial lung findings compatible with interstitial lung disease.
Read More
Antidepressant Often Prescribed Off-label Fails to Ease Breathlessness in Respiratory Patients
Patients receiving the drug also had slightly more side effects and needed more care from hospitals and family members.
Read MoreInvestigational Antibody Treatment Shows Promise for Fibrotic Lung Diseases
Preclinical data reveals CAN10’s potential to target key proteins involved in systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis.
Read More
Could Arthritis Drugs Alleviate Long COVID Lung Symptoms?
Researchers have identified a potential treatment for the respiratory symptoms of long COVID by discovering an unknown cause of the condition within the lungs.
Read More
Congress Introduces SOAR Act to Improve Supplemental Oxygen Access
The Supplemental Oxygen Access Reform Act of 2024, designed to ease access to supplemental oxygen for Medicare beneficiaries, was introduced in the US House of Representatives by a bipartisan group of members of Congress.
Read More
Model Created to Decode ABCA3 Mutation’s Role in Childhood Lung Disease
Researchers demonstrate how they can now study the most common genetic cause of pediatric interstitial lung disease using stem cells generated from each patient.
Read More
FDA Clears AI-Powered Idiopathic Pulmonary Fibrosis Diagnostic
According to Imvaria, the device’s manufacturer, the clearance signifies the first FDA authorization of a diagnostic tool of any type in lung fibrosis.
Read More
Omega-3 Fatty Acids May Slow Pulmonary Fibrosis
Higher levels of omega-3 fatty acids were associated with better lung function and longer transplant-free survival in patients with pulmonary fibrosis, a new study finds.
Read More
New Guidance for Treating Systemic Sclerosis-associated ILD
A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.
Read More
Guidance for Diagnosis and Treatment of Pulmonary Hypertension Related to ILD
The Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the diagnosis and treatment of patients living with pulmonary hypertension related to interstitial lung disease.
Read More
CHEST Awards Grants to Accelerate ILD Diagnosis
CHEST announced the recipients of quality improvement grants aimed at shortening the time to diagnosis for interstitial lung disease.
Read More
ILD Diagnostic Validated in Two New Studies Presented at CHEST
Two studies presented at CHEST 2023 validated the effectiveness of the Envisia Genomic Classifier in improving the detection of interstitial lung disease.
Read More
7 New Sites Join PFF Care Center Network
The Pulmonary Fibrosis Foundation announced that seven medical centers have joined the PFF Care Center Network as clinical associate members, a new membership option.
Read More
Cleveland Clinic Pulmonologist Takes Helm at Pulmonary Fibrosis Foundation
The Pulmonary Fibrosis Foundation announced Franck Rahaghi, MD, MHS, FCCP, as its incoming president, CEO, and chief medical officer, effective Sept 15.
Read More
Pulmonary Rehabilitation Gets ‘Strong’ Recommendation in New ATS Guideline
The latest guideline from the American Thoracic Society reaffirms benefits for patients with COPD as well as pulmonary hypertension and interstitial lung disease.
Read More
FDA Greenlights Phase 2 Trial of OATD-01 for Pulmonary Sarcoidosis
The phase 2 clinical trial is expected to be a multi-center, randomized, double-blind, placebo-controlled study assessing the drug’s safety and effectiveness in treating approximately 90 pulmonary sarcoidosis patients.
Read More
aTyr Announces Phase 2 Study of SSc-ILD Drug
The expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read More